Document is current
Any future updates will be listed below
-
Authors
Wang, Chengyu https://orcid.org/0000-0003-0516-332X
Lan, Xiaofeng
Liu, Weijian
Zhan, Yanni
Zheng, Wei https://orcid.org/0000-0003-2371-4789
Chen, Xiaoyu https://orcid.org/0000-0001-5785-198X
Liu, Guanxi
Mai, Siming
Lu, Hanna https://orcid.org/0000-0002-9090-258X
McIntyre, Roger S.
Zhou, Yanling https://orcid.org/0000-0002-8741-9394
Ning, Yuping https://orcid.org/0000-0002-5727-2782
- License Information
-
More Information
Article History
Received: 22 June 2023
Revised: 9 May 2024
Accepted: 17 July 2024
First Online: 6 August 2024
Competing interests
: RSM has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. He is the CEO of Braxia Scientific Corp. All the remaining authors have nothing to disclose.
: The study was approved by the Clinical Research Ethics Committee of the Affiliated Brain Hospital of Guangzhou Medical University and was conducted in accordance with the ethical principles based on the Declaration of Helsinki. Informed consent was obtained from all participants before the study.
